HCAT - Health Catalyst Inc Stock Price, Fair Value and News

6.81USD+0.40 (+6.24%)Market Closed

Market Summary

USD6.81+0.40

Market Closed

6.24%

HCAT Alerts

Big jump in Earnings (Y/Y)

Losses in recent quarter

HCAT Stock Price

View Fullscreen

HCAT RSI Chart

HCAT Valuation

Market Cap

402.0M

Price/Earnings (Trailing)

-3.81

Price/Sales (Trailing)

1.35

Price/Free Cashflow

-22.03

HCAT Price/Sales (Trailing)

HCAT Profitability

Return on Equity

-29.55%

Return on Assets

-15.18%

Free Cashflow Yield

-4.54%

HCAT Fundamentals

HCAT Revenue

Revenue (TTM)

296.8M

Rev. Growth (Yr)

1.16%

Rev. Growth (Qtr)

-0.48%

HCAT Earnings

Earnings (TTM)

-105.5M

Earnings Growth (Yr)

37.97%

Earnings Growth (Qtr)

32.08%

Breaking Down HCAT Revenue

Last 7 days

-2.0%

Last 30 days

11.8%

Last 90 days

-29.1%

Trailing 12 Months

-34.3%

How does HCAT drawdown profile look like?

HCAT Financial Health

Current Ratio

4.31

Debt/Equity

0.64

Debt/Cashflow

-0.08

HCAT Investor Care

Shares Dilution (1Y)

4.93%

Diluted EPS (TTM)

-1.84

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	296.8M	0	0	0
2023	282.0M	284.6M	290.0M	295.9M
2022	254.2M	265.2M	271.8M	276.2M
2021	199.6M	215.9M	230.5M	241.9M
2020	164.8M	171.3M	179.1M	188.8M
2019	127.2M	141.0M	147.5M	154.9M
2018	0	86.2M	99.4M	112.6M
2017	0	0	0	73.1M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Health Catalyst Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 15, 2024	llewelyn linda	sold	-12,250	6.11	-2,005	chief people officer
Mar 15, 2024	llewelyn linda	sold	-15,647	7.8043	-2,005	chief people officer
Mar 01, 2024	burton daniel d.	sold (taxes)	-40,038	8.0512	-4,973	chief executive officer
Mar 01, 2024	landry benjamin	sold (taxes)	-26,689	8.0512	-3,315	general counsel
Mar 01, 2024	llewelyn linda	sold (taxes)	-27,688	8.0512	-3,439	chief people officer
Mar 01, 2024	alger jason	sold (taxes)	-19,918	8.0512	-2,474	chief financial officer
Mar 01, 2024	freeman kevin lee	sold (taxes)	-36,552	8.0512	-4,540	chief commercial officer
Mar 01, 2024	alger jason	acquired	-	-	70,000	chief financial officer
Mar 01, 2024	hunt bryan truman	sold (taxes)	-94,070	8.0512	-11,684	chief financial officer
Mar 01, 2024	lesueur daniel	acquired	-	-	70,000	chief operating officer

Which funds bought or sold HCAT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	PNC Financial Services Group, Inc.	added	2,900	15,815	16,491	-%
May 10, 2024	DIMENSIONAL FUND ADVISORS LP	added	5.32	-2,057,660	12,267,800	-%
May 10, 2024	PIER 88 INVESTMENT PARTNERS LLC	added	27.32	9,521	278,987	0.07%
May 10, 2024	WELLS FARGO & COMPANY/MN	added	11.63	-18,780	184,885	-%
May 10, 2024	VANGUARD GROUP INC	reduced	-18.73	-17,297,800	33,706,000	-%
May 10, 2024	Covestor Ltd	added	66.67	-	-	-%
May 10, 2024	ACADIAN ASSET MANAGEMENT LLC	added	38.26	603,000	5,453,000	0.02%
May 10, 2024	CITIGROUP INC	reduced	-70.99	-274,612	84,796	-%
May 10, 2024	OSAIC HOLDINGS, INC.	reduced	-72.07	-40,873	12,009	-%
May 10, 2024	Campbell & CO Investment Adviser LLC	new	-	164,335	164,335	0.01%

Are Funds Buying or Selling HCAT?

Are funds buying HCAT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own HCAT

No. of Funds

Unveiling Health Catalyst Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	point72 asset management, l.p.	7.2%	4,157,366	SC 13G/A
Feb 13, 2024	vanguard group inc	9.57%	5,507,972	SC 13G/A
Feb 08, 2024	wellington management group llp	5.58%	3,213,413	SC 13G
Jan 24, 2024	blackrock inc.	9.2%	5,318,571	SC 13G/A
Jul 27, 2023	point72 asset management, l.p.	5.0%	2,824,198	SC 13G
Feb 14, 2023	alliancebernstein l.p.	0.2%	134,154	SC 13G/A
Feb 14, 2023	point72 asset management, l.p.	2.9%	1,566,000	SC 13G/A
Feb 13, 2023	capital research global investors	1.0%	568,785	SC 13G/A
Feb 09, 2023	vanguard group inc	11.09%	6,069,528	SC 13G/A
Feb 06, 2023	wellington management group llp	2.53%	1,385,432	SC 13G/A

Recent SEC filings of Health Catalyst Inc

View All Filings

Date Filed	Form Type	Document
May 10, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	DEFA14A	DEFA14A
Apr 23, 2024	10-K/A	Annual Report
Apr 17, 2024	4	Insider Trading
Apr 15, 2024	144	Notice of Insider Sale Intent
Mar 19, 2024	4	Insider Trading
Mar 15, 2024	144	Notice of Insider Sale Intent
Mar 05, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Health Catalyst Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
UNH	471.0B	379.5B	16.52%	4.18%	30.66	1.24	12.96%	-25.81%
CI	99.2B	206.0B	-0.19%	36.09%	25.74	0.48	12.55%	-43.95%
HCA	83.1B	66.7B	-1.75%	14.97%	15.19	1.25	9.59%	-4.59%
CVS	70.9B	360.9B	-17.72%	-17.64%	9.68	0.2	9.07%	78.49%
CNC	41.2B	155.5B	9.05%	14.83%	15.05	0.26	6.34%	84.42%
UHS	12.0B	14.7B	7.08%	28.00%	14.7	0.82	7.99%	19.23%
DVA	12.0B	12.3B	4.75%	45.76%	14.69	0.97	5.77%	58.74%
MID-CAP
CHE	8.6B	2.3B	-8.04%	3.95%	30.35	3.75	5.96%	18.29%
ACHC	6.6B	3.0B	-2.06%	0.60%	-588.47	2.22	10.92%	-104.06%
AMN	2.2B	3.5B	4.31%	-36.95%	15.6	0.64	-27.67%	-62.43%
AMEH	2.2B	1.5B	-3.93%	16.78%	35.11	1.51	19.34%	40.15%
SMALL-CAP
ADUS	1.8B	1.1B	13.13%	28.86%	27.6	1.67	11.45%	30.74%
BKD	1.3B	3.0B	8.04%	87.90%	-7.75	0.44	4.98%	4.88%
BEAT	52.7M	-	2.56%	-3.85%	-3.49	-	-	-1.05%
AMS	22.1M	21.3M	19.11%	26.45%	41.45	1.04	8.00%	-62.25%

Health Catalyst Inc News

Latest updates

Health Catalyst Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-0.5%	74,723	75,084	73,773	73,213	73,868	69,162	68,354	70,633	68,087	64,716	61,737	59,627	55,846	53,279	47,191	43,259	45,116	43,501	39,423	36,804	35,213
Operating Expenses	-6.8%	59,018	63,293	56,566	68,393	70,478	67,801	77,735	69,218	58,438	75,604	70,900	61,893	52,825	65,673	46,297	35,770	39,153	35,496	41,527	28,457	28,981
S&GA Expenses	10.3%	19,058	17,271	15,084	16,397	18,569	20,373	25,401	20,922	20,818	21,863	20,808	16,705	15,651	14,793	14,629	12,502	13,487	11,705	14,721	10,385	10,473
R&D Expenses	-26.7%	14,871	20,288	17,667	17,590	17,082	19,614	20,770	18,148	17,148	17,479	16,385	14,524	14,345	14,978	13,390	12,061	13,088	13,043	13,477	9,710	10,022
Income Taxes	-21.0%	113	143	59.00	85.00	69.00	84.00	156	-944	-3,600	-173	-6,658	-192	101	24.00	14.00	4.00	-1,236	99.00	21.00	11.00	11.00
Net Income	32.1%	-20,587	-30,312	-22,032	-32,613	-33,190	-35,782	-45,735	-33,428	-22,458	-48,992	-40,014	-35,834	-28,370	-43,018	-27,326	-27,183	-17,490	-14,266	-21,416	-10,694	-13,720
Net Income Margin	10.9%	-0.36*	-0.40*	-0.43*	-0.52*	-0.53*	-0.50*	-0.55*	-0.55*	-0.58*	-0.63*	-0.64*	-	-	-	-	-	-	-	-	-	-
Free Cashflow	152.1%	10,058	-19,296	2,966	-11,981	-6,005	-15,236	-13,225	-9,778	802	-10,398	-7,049	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4
Assets	-1.0%	695	702	713	723	752	752	776	811	825	832	846	563	571	578	571	466	309	302	320	140	111
Current Assets	1.0%	397	393	408	411	435	428	443	465	482	508	515	321	325	330	323	397	250	264	280	95.00	67.00
Cash Equivalents	89.5%	201	106	95.00	116	133	116	124	177	198	193	276	205	133	92.00	111	104	61.00	18.00	52.00	21.00	28.00
Net PPE	-3.9%	25.00	26.00	26.00	26.00	26.00	26.00	25.00	27.00	25.00	23.00	21.00	20.00	19.00	13.00	5.00	4.00	4.00	4.00	4.00	4.00	5.00
Goodwill	0%	191	191	5.00	186	186	186	186	186	180	170	170	62.00	108	108	108	18.00	18.00	4.00	4.00	-	-
Liabilities	0.9%	338	335	331	333	347	327	336	342	344	310	296	287	302	302	271	232	105	102	113	112	76.00
Current Liabilities	3.6%	92.00	89.00	84.00	87.00	102	83.00	91.00	90.00	93.00	93.00	263	255	259	88.00	66.00	50.00	50.00	48.00	53.00	51.00	42.00
Long Term Debt	0.2%	228	228	228	227	227	227	226	226	225	181	-	-	-	169	166	163	48.00	48.00	48.00	48.00	19.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.00
LT Debt, Non Current	-100.0%	-	228	228	227	227	227	226	226	225	181	-	-	-	169	166	163	48.00	48.00	48.00	48.00	19.00
Shareholder's Equity	-2.6%	357	367	382	390	405	425	440	469	481	522	549	276	269	276	300	234	204	201	207	-	-
Retained Earnings	-1.8%	-1,137	-1,117	-1,086	-1,064	-1,032	-999	-963	-917	-884	-878	-829	-789	-754	-725	-682	-655	-628	-610	-596	-557	-374
Additional Paid-In Capital	-	-	-	-	-	-	-	1,404	1,387	1,365	1,401	1,379	1,066	1,023	1,002	982	889	832	811	803	-	-
Shares Outstanding	1.1%	59.00	58.00	57.00	57.00	56.00	55.00	54.00	54.00	53.00	47.00	49.00	-	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	688	-	-	-	783	-	-	-	2,500	-	-	-	946	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	153.9%	10,266	-19,041	3,115	-11,574	-5,580	-14,821	-12,031	-9,576	1,158	-9,775	-5,360	-4,845	-3,143	-4,141	-4,487	-751	-16,769	-13,061	-5,482	-8,417	-5,224
Share Based Compensation	-16.7%	10,838	13,011	14,232	14,629	13,884	18,748	17,304	17,932	18,120	16,421	17,487	17,727	13,510	10,674	9,496	9,046	8,741	4,816	9,974	1,398	1,656
Cashflow From Investing	180.7%	83,984	29,917	-24,858	-7,415	22,649	6,256	-33,182	-13,751	1,656	-76,683	-172,794	72,423	37,376	-21,905	-3,976	-106,830	50,146	-22,070	-157,318	-1,558	-28,656
Cashflow From Financing	118.5%	863	395	1,040	1,202	93.00	637	-7,539	1,901	2,388	3,916	248,833	4,889	6,446	6,740	15,503	150,779	9,587	1,098	194,040	-1,414	37,657
Buy Backs	-	-	-	-	-	1,808	-	8,393	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

HCAT Income Statement

2024-03-31

Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands

3 Months Ended

Mar. 31, 2024

Mar. 31, 2023

Revenue:

Total revenue

^[1]

$ 74,723

$ 73,868

Cost of revenue, excluding depreciation and amortization:

Total cost of revenue, excluding depreciation and amortization

38,517

38,304

Operating expenses:

Sales and marketing

19,058

18,569

Research and development

14,871

17,082

General and administrative

14,564

23,833

Depreciation and amortization

10,525

10,994

Total operating expenses

59,018

70,478

Loss from operations

(22,812)

(34,914)

Interest and other income, net

2,338

1,793

Loss before income taxes

(20,474)

(33,121)

Income tax provision

113

Net loss

$ (20,587)

$ (33,190)

Net loss per share, basic (in USD per share)

$ (0.35)

$ (0.60)

Net loss per share, diluted (in USD per share)

$ (0.35)

$ (0.60)

Weighted-average shares outstanding used in calculating net loss per share, basic (in shares)

58,591,514

55,484,835

Weighted-average shares outstanding used in calculating net loss per share, diluted (in shares)

58,591,514

55,484,835

Technology

Revenue:

Total revenue

^[1]

$ 46,966

$ 47,186

Cost of revenue, excluding depreciation and amortization:

Total cost of revenue, excluding depreciation and amortization

15,315

14,727

Professional services

Revenue:

Total revenue

^[1]

27,757

26,682

Cost of revenue, excluding depreciation and amortization:

Total cost of revenue, excluding depreciation and amortization

$ 23,202

$ 23,577

[1]	Includes amounts attributable to related party transactions. See Note 17 for further details.

HCAT Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands

Mar. 31, 2024

Dec. 31, 2023

Current assets:

Cash and cash equivalents

$ 201,370

$ 106,276

Short-term investments

126,415

211,452

Accounts receivable, net

^[1]

53,874

60,290

Prepaid expenses and other assets

15,477

15,379

Total current assets

397,136

393,397

Property and equipment, net

24,697

25,712

Intangible assets, net

66,217

73,384

Operating lease right-of-use assets

12,003

13,927

Goodwill

190,652

Other assets

4,407

4,742

Total assets

695,112

701,814

Current liabilities:

Accounts payable

5,697

6,641

Accrued liabilities

19,614

23,282

Deferred revenue

^[1]

63,550

55,753

Operating lease liabilities

3,347

3,358

Total current liabilities

92,208

89,034

Convertible senior notes

228,413

228,034

Deferred revenue, net of current portion

Operating lease liabilities, net of current portion

17,112

17,676

Other liabilities

Total liabilities

337,902

334,895

Commitments and contingencies (Note 15)

Stockholders’ equity:

Preferred stock, $0.001 par value per share; 25,000,000 shares authorized and no shares issued and outstanding as of March 31, 2024 and December 31, 2023

Common stock, $0.001 par value per share, and additional paid-in capital; 500,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 58,956,132 and 58,295,491 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively

1,495,091

1,484,056

Accumulated deficit

(1,137,757)

(1,117,170)

Accumulated other comprehensive income (loss)

(124)

Total stockholders’ equity

357,210

366,919

Total liabilities and stockholders’ equity

$ 695,112

$ 701,814

[1]	Includes amounts attributable to related party transactions. See Note 17 for further details.

About Health Catalyst Inc

Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company offers data operating system data platform for analytics, and application development and interoperability that provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications designed to analyze the problems faced across clinical and quality, population health, and financial and operational use cases. It also provides services expertise, which include data and analytics, domain expertise and education, tech-enabled managed, and implementation services; and opportunity analysis and prioritization, data governance, data modeling and analysis, quality and process improvement strategy, cost accounting, data abstraction, and population health strategies. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is based in South Jordan, Utah.

CEO	Mr. Daniel D. Burton
WEBSITE	healthcatalyst.com
INDUSTRY	Healthcare Plans
EMPLOYEES	1200

Health Catalyst Inc Frequently Asked Questions

What is the ticker symbol for Health Catalyst Inc? What does HCAT stand for in stocks?

HCAT is the stock ticker symbol of Health Catalyst Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Health Catalyst Inc (HCAT)?

As of Mon May 13 2024, market cap of Health Catalyst Inc is 402.03 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HCAT stock?

You can check HCAT's fair value in chart for subscribers.

What is the fair value of HCAT stock?

You can check HCAT's fair value in chart for subscribers. The fair value of Health Catalyst Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Health Catalyst Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for HCAT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Health Catalyst Inc a good stock to buy?

The fair value guage provides a quick view whether HCAT is over valued or under valued. Whether Health Catalyst Inc is cheap or expensive depends on the assumptions which impact Health Catalyst Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HCAT.

What is Health Catalyst Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 13 2024, HCAT's PE ratio (Price to Earnings) is -3.81 and Price to Sales (PS) ratio is 1.35. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HCAT PE ratio will change depending on the future growth rate expectations of investors.